Author： Kolaja Kyle L Kramer Jeffrey A
Publisher： Informa Healthcare
ISSN： 1474-0338
Source： Expert Opinion on Drug Safety, Vol.1, Iss.3, 2002-09, pp. : 275-286
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Toxicogenomics in drug safety assessment
By Hewitt Philip Walijew Alexandra
Pharmacogenomics, Vol. 9, Iss. 4, 2008-04 ,pp. :
Access to resources
Recommend
Drug safety evaluation of defibrotide
Expert Opinion on Drug Safety, Vol. 12, Iss. 1, 2013-01 ,pp. :
Drug safety evaluation of amlodipine
By Derosa Giuseppe Maffioli Pamela
Expert Opinion on Drug Safety, Vol. 10, Iss. 5, 2011-09 ,pp. :
Drug safety evaluation of exemestane
By Lintermans Anneleen Neven Patrick Paridaens Robert
Expert Opinion on Drug Safety, Vol. 10, Iss. 3, 2011-05 ,pp. :
A drug safety evaluation of valsartan
By Fogari Roberto Zoppi Annalisa
Expert Opinion on Drug Safety, Vol. 10, Iss. 2, 2011-03 ,pp. :